GlaxoSmithKline PLC ADR (GSK)vsQMMM Holdings Limited Ordinary Shares (QMMM)
GSK
GlaxoSmithKline PLC ADR
$50.41
-0.18%
HEALTHCARE · Cap: $101.38B
QMMM
QMMM Holdings Limited Ordinary Shares
$119.40
0.00%
COMMUNICATION SERVICES · Cap: $6.83B
Smart Verdict
WallStSmart Research — data-driven comparison
GlaxoSmithKline PLC ADR generates 1746955% more annual revenue ($32.78B vs $1.88M). GSK leads profitability with a 17.8% profit margin vs -150.1%. GSK earns a higher WallStSmart Score of 66/100 (B-).
GSK
Strong Buy66
out of 100
Grade: B-
QMMM
Avoid14
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-3.1%
Fair Value
$56.71
Current Price
$50.41
$6.30 premium
Intrinsic value data unavailable for QMMM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 41 in profit
Strong operational efficiency at 36.3%
Large-cap with strong market position
Attractively priced relative to earnings
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
1.5% revenue growth
Elevated debt levels
Distress zone — elevated risk
0.0% earnings growth
Weak financial health signals
Trading at 519.1x book value
ROE of -198.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : GSK
The strongest argument for GSK centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 17.8% and operating margin at 36.3%. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bull Case : QMMM
The strongest argument for QMMM centers on Debt/Equity, Altman Z-Score.
Bear Case : GSK
The primary concerns for GSK are Revenue Growth, Debt/Equity, Altman Z-Score.
Bear Case : QMMM
The primary concerns for QMMM are EPS Growth, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
GSK profiles as a value stock while QMMM is a turnaround play — different risk/reward profiles.
GSK is growing revenue faster at 1.5% — sustainability is the question.
GSK generates stronger free cash flow (698M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
GSK scores higher overall (66/100 vs 14/100), backed by strong 17.8% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GlaxoSmithKline PLC ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
QMMM Holdings Limited Ordinary Shares
COMMUNICATION SERVICES · ADVERTISING AGENCIES · USA
QMMM Holdings Limited, provides digital media advertising and marketing production services primarily in Hong Kong.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?